Over a 10-year period, the Gene Therapy Resource Program (GTRP) of the National Heart Lung and Blood Institute has provided a set of core services to investigators to facilitate the clinical translation of gene therapy. These services have included a preclinical (research-grade) vector production core; current Good Manufacturing Practice clinical-grade vector cores for recombinant adeno-associated virus and lentivirus vectors; a pharmacology and toxicology core; and a coordinating center to manage program logistics and to provide regulatory and financial support to early-phase clinical trials. In addition, the GTRP has utilized a Steering Committee and a Scientific Review Board to guide overall progress and effectiveness and to evaluate individual proposals. These resources have been deployed to assist 82 investigators with 172 approved service proposals. These efforts have assisted in clinical trial implementation across a wide range of genetic, cardiac, pulmonary, and blood diseases. Program outcomes and potential future directions of the program are discussed.
Get full access to this article
View all access options for this article.
References
1.
WooSL, SkarlatosSI, JoyceMM, et al.Critical resources for gene therapy in heart, lung, and blood diseases working group. Mol Ther, 2006; 13:641–643.
2.
McDonaldCL, BensonJ, CornettaK, et al.Advancing translational research through the NHLBI Gene Therapy Resource Program (GTRP). Hum Gene Ther Clin Dev, 2013; 24:5–10.
3.
BodenJ, Lassance-SoaresRM, WangH, et al.Vascular regeneration in ischemic hindlimb by adeno-associated virus expressing conditionally silenced vascular endothelial growth factor. J Am Heart Assoc, 2016; 5:e001815.
4.
LiZ, LiY, ChakrabortyM, et al.Liver-specific deficiency of serine palmitoyltransferase subunit 2 decreases plasma sphingomyelin and increases apolipoprotein E levels. J Biol Chem, 2009; 284:27010–27019.
5.
ReyS, LeeK, WangCJ, et al.Synergistic effect of HIF-1alpha gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia. Proc Natl Acad Sci U S A, 2009; 106:20399–20404.
6.
SarkarK, Fox-TalbotK, SteenbergenC, et al.Adenoviral transfer of HIF-1alpha enhances vascular responses to critical limb ischemia in diabetic mice. Proc Natl Acad Sci U S A, 2009; 106:18769–18774.
7.
AlexanderET, WeibelGL, JoshiMR, et al.Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano. Arterioscler Thromb Vasc Biol, 2009; 29:1496–1501.
8.
BurkhardtR, TohSA, LagorWR, et al.Trib1 is a lipid- and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice. J Clin Invest, 2010; 120:4410–4414.
9.
MusunuruK, StrongA, Frank-KamenetskyM, et al.From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature, 2010; 466:714–719.
10.
LagorWR, FieldsDW, KhetarpalSA, et al.The effects of apolipoprotein F deficiency on high density lipoprotein cholesterol metabolism in mice. PloS One, 2012; 7:e31616.
11.
XieY, WangT, SunGY, et al.Specific disruption of astrocytic Ca2+ signaling pathway in vivo by adeno-associated viral transduction. Neuroscience, 2010; 170:992–1003.
12.
WhiteJD, ThesierDM, SwainJB, et al.Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo. Gene Ther, 2011; 18:546–552.
13.
KatzMG, SwainJD, FargnoliAS, BridgesCR. Gene therapy during cardiac surgery: role of surgical technique to minimize collateral organ gene expression. Interact Cardiovasc Thorac Surg, 2010; 11:727–731.
14.
PankajakshanD, MakindeTO, GauravR, et al.Successful transfection of genes using AAV-2/9 vector in swine coronary and peripheral arteries. J Surg Res, 2012; 175:169–175.
15.
HasanA, PokezaN, ShawL, et al.The matricellular protein cysteine-rich protein 61 (CCN1/Cyr61) enhances physiological adaptation of retinal vessels and reduces pathological neovascularization associated with ischemic retinopathy. J Biol Chem, 2011; 286:9542–9554.
16.
MuenznerM, TuviaN, DeutschmannC, et al.Retinol-binding protein 4 and its membrane receptor STRA6 control adipogenesis by regulating cellular retinoid homeostasis and retinoic acid receptor alpha activity. Mol Cell Biol, 2013; 33:4068–4082.
17.
FargnoliAS, KatzMG, WilliamsRD, et al.A needleless liquid jet injection delivery method for cardiac gene therapy: a comparative evaluation versus standard routes of delivery reveals enhanced therapeutic retention and cardiac specific gene expression. J Cardiovasc Transl Res, 2014; 7:756–767.
18.
JoyeuxL, DanzerE, LimberisMP, et al.In utero lung gene transfer using adeno-associated viral and lentiviral vectors in mice. Hum Gene Ther Methods, 2014; 25:197–205.
19.
StitelmanDH, BrazeltonT, BoraA, et al.Developmental stage determines efficiency of gene transfer to muscle satellite cells by in utero delivery of adeno-associated virus vector serotype 2/9. Mol Ther Methods Clin Dev, 2014; 1:14040.
20.
FanY, YangYL, YehCC, et al.Spacial and temporal patterns of gene expression after cardiac MEK1 gene transfer improve post-infarction remodeling without inducing global hypertrophy. J Cell Biochem, 2017; 118:775–784.
21.
GubrijIB, MartinSR, PangleAK, et al.Attenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthase. Hum Gene Ther, 2014; 25:498–505.
22.
YanL, LeeS, LazzaroDR, et al.Single and compound knock-outs of MicroRNA (miRNA)-155 and its angiogenic gene target CCN1 in mice alter vascular and neovascular growth in the retina via resident microglia. J Biol Chem, 2015; 290:23264–23281.
23.
GeguchadzeRN, MachenL, ZoureliasL, et al.An AAV2/5 vector enhances safety of gene transfer to the mouse salivary gland. J Dent Res, 2012; 91:382–386.
24.
StrongA, DingQ, EdmondsonAC, et al.Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest, 2012; 122:2807–2816.
25.
KhetarpalSA, SchjoldagerKT, ChristoffersenC, et al.Loss of function of GALNT2 lowers high-density lipoproteins in humans, nonhuman primates, and rodents. Cell Metab, 2016; 24:234–245.
26.
ShinJH, YueY, SmithB, et al.Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs. Hum Gene Ther, 2012; 23:287–294.
27.
ShinJH, YueY, SrivastavaA, et al.A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs. Hum Gene Ther, 2012; 23:202–209.
28.
YueY, PanX, HakimCH, et al.Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum Mol Genet, 2015; 24:5880–5890.
29.
ChintalaH, LiuH, ParmarR, et al.Connective tissue growth factor regulates retinal neovascularization through p53 protein-dependent transactivation of the matrix metalloproteinase (MMP)-2 gene. J Biol Chem, 2012; 287:40570–40585.
30.
LiH, DhanasekaranP, AlexanderET, et al.Molecular mechanisms responsible for the differential effects of apoE3 and apoE4 on plasma lipoprotein-cholesterol levels. Arterioscler Thromb Vasc Biol, 2013; 33:687–693.
31.
GranseeHM, Gonzalez PorrasMA, ZhanWZ, et al.Motoneuron glutamatergic receptor expression following recovery from cervical spinal hemisection. J Comp Neurol, 2017; 525:1192–1205.
32.
GranseeHM, ZhanWZ, SieckGC, et al.Targeted delivery of TrkB receptor to phrenic motoneurons enhances functional recovery of rhythmic phrenic activity after cervical spinal hemisection. PloS One, 2013; 8:e64755.
33.
Martinez-GalvezG, ZambranoJM, Diaz SotoJC, et al.TrkB gene therapy by adeno-associated virus enhances recovery after cervical spinal cord injury. Exp Neurol, 2016; 276:31–40.
34.
TurnerAM, AckleyAM, MatroneMA, et al.Characterization of an HIV-targeted transcriptional gene-silencing RNA in primary cells. Hum Gene Ther, 2012; 23:473–483.
35.
ShinJH, PanX, HakimCH, et al.Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy. Mol Ther, 2013; 21:750–757.
36.
FargnoliAS, KatzMG, YarnallC, et al.Cardiac surgical delivery of the sarcoplasmic reticulum calcium ATPase rescues myocytes in ischemic heart failure. Ann Thorac Surg, 2013; 96:586–595.
37.
KatzMG, FargnoliAS, WilliamsRD, et al.Safety and efficacy of high-dose adeno-associated virus 9 encoding sarcoplasmic reticulum Ca(2+) adenosine triphosphatase delivered by molecular cardiac surgery with recirculating delivery in ovine ischemic cardiomyopathy. J Thorac Cardiovasc Surg, 2014; 148:1065–1072, 1073e1–2; discussion 1072–1073.
FlotteTR, MuellerC. What is suppression of anti-adeno-associated virus capsid T-cells achieving?. Hum Gene Ther, 2014; 25:178–179.
40.
GruntmanAM, SuL, SuQ, et al.Stability and compatibility of recombinant adeno-associated virus under conditions commonly encountered in human gene therapy trials. Hum Gene Ther Methods, 2015; 26:71–76.
41.
FlotteTR, TrapnellBC, HumphriesM, et al.Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther, 2011; 22:1239–1247.
42.
WangG, YoungSP, BaliD, et al.Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease. Mol Ther Methods Clin Dev, 2014; 1:14018.
43.
ChiuchioloMJ, KaminskySM, SondhiD, et al.Intrapleural administration of an AAVrh.10 vector coding for human alpha1-antitrypsin for the treatment of alpha1-antitrypsin deficiency. Hum Gene Ther Clin Dev, 2013; 24:161–173.
44.
WangG, EvansCH, BensonJM, et al.Safety and biodistribution assessment of sc-rAAV2.5IL-1Ra administered via intra-articular injection in a mono-iodoacetate-induced osteoarthritis rat model. Mol Ther Methods Clin Dev, 2016; 3:15052.
45.
GugginoW, BensonJ, SeagraveJ, et al.A preclinical study in rhesus macaques for cystic fibrosis to assess gene transfer and transduction by AAV1 and AAV5 with a dual-luciferase reporter system. Hum Gene Ther Clin Dev, 2017; 28:145–156.
46.
SinnPL, CooneyAL, OaklandM, et al.Lentiviral vector gene transfer to porcine airways. Mol Ther Nucleic Acids, 2012; 1:e56.
47.
CarbonaroDA, ZhangL, JinX, et al.Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. Mol Ther, 2014; 22:607–622.
48.
ElmallahMK, FalkDJ, NayakS, et al.Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Mol Ther, 2014; 22:702–712.
49.
SmithBK, CollinsSW, ConlonTJ, et al.Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther, 2013; 24:630–640.
50.
HammondHK, PennyWF, TraverseJH, et al.Intracoronary gene transfer of adenylyl xyclase 6 in patients with heart failure: a randomized clinical trial. JAMA Cardiol, 2016; 1:163–171.
51.
KatwalAB, KonkalmattPR, PirasBA, et al.Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery. Gene Ther, 2013; 20:930–938.
52.
LeeA, JeongD, MitsuyamaS, et al.The role of SUMO-1 in cardiac oxidative stress and hypertrophy. Antioxid Redox Signal, 2014; 21:1986–2001.
53.
WahlquistC, JeongD, Rojas-MunozA, et al.Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature, 2014; 508:531–535.
54.
TilemannL, LeeA, IshikawaK, et al.SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure. Sci Transl Med, 2013; 5:211ra159.
55.
BenardL, OhJG, CacheuxM, et al.Cardiac stim1 silencing impairs adaptive hypertrophy and promotes heart failure through inactivation of mTORC2/Akt signaling. Circulation, 2016; 133:1458–1471; discussion 1471.
56.
AgueroJ, HadriL, HammoudiN, et al.Inhaled gene transfer for pulmonary circulation. Methods Mol Biol, 2017; 1521:339–349.
57.
BonnetG, IshikawaK, HajjarRJ, et al.Direct myocardial injection of vectors. Methods Mol Biol, 2017; 1521:237–248.
58.
WatanabeS, LeonardsonL, HajjarRJ, et al.Cardiac gene delivery in large animal models: antegrade techniques. Methods Mol Biol, 2017; 1521:227–235.
59.
Del MonteF, IshikawaK, HajjarRJ. Gene transfer to rodent hearts in vivo. Methods Mol Biol, 2017; 1521:195–204.
60.
StillitanoF, KarakikesI, HajjarRJ. Gene transfer in cardiomyocytes derived from ES and iPS cells. Methods Mol Biol, 2017; 1521:183–193.
61.
YooJ, HajjarRJ, JeongD. Generation of efficient miRNA inhibitors using tough decoy constructs. Methods Mol Biol, 2017; 1521:41–53.
62.
IshikawaK, HajjarRJ. Current methods in cardiac gene therapy: overview. Methods Mol Biol, 2017; 1521:3–14.
63.
GruntmanAM, FlotteTR. Delivery of adeno-associated virus gene therapy by intravascular limb infusion methods. Hum Gene Ther Clin Dev, 2015; 26:159–164.
64.
CortiM, CleaverB, ClementN, et al.Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in Pompe disease: preclinical to clinical planning. Hum Gene Ther Clin Dev, 2015; 26:185–193.
65.
WilcoxDA. Megakaryocyte- and megakaryocyte precursor-related gene therapies. Blood, 2016; 127:1260–1268.
66.
SmithBK, MartinAD, LawsonLA, et al.Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: clinical evidence of respiratory plasticity. Exp Neurol, 2017; 287:216–224.
